Novavax Covid vaccine highly effective, but not against S.Africa variant

Washington (AFP) – US biotech firm Novavax said Thursday its two-shot Covid-19 vaccine showed an overall efficacy of 89.3 percent in a major Phase 3 clinical trial in Britain, and remained highly effective against a variant first identified there. But the positive news was partly offset by other results that showed it offered significantly less protection against a highly transmissible variant of the coronavirus first identified in South Africa, which is spreading rapidly around the world. Novavax said it began working on new vaccines against emerging strains in early January and expects to se…

Read More

HEDGE accordingly